-
C414475-5mgInformationCB-103 CB-103 is an orally active inhibitor of the Notch transcription activation complex. CB-103 produces Notch loss-of-function phenotypes in flies and mice and inhibits the growth of human breast cancer and leukemia
-
C174237-100mgBiochemical mechanism:Cell permeable: yesPrimary TargetGLS1Reversible: yesTarget IC50: 23 nM &: 28 nM, respectively, using murine kidney and brain homogenates.
-
C174237-10mgBiochemical mechanism:Cell permeable: yesPrimary TargetGLS1Reversible: yesTarget IC50: 23 nM &: 28 nM, respectively, using murine kidney and brain homogenates.
-
C174237-250mgBiochemical mechanism:Cell permeable: yesPrimary TargetGLS1Reversible: yesTarget IC50: 23 nM &: 28 nM, respectively, using murine kidney and brain homogenates.
-
C174237-25mgBiochemical mechanism:Cell permeable: yesPrimary TargetGLS1Reversible: yesTarget IC50: 23 nM &: 28 nM, respectively, using murine kidney and brain homogenates.
-
C174237-50mgBiochemical mechanism:Cell permeable: yesPrimary TargetGLS1Reversible: yesTarget IC50: 23 nM &: 28 nM, respectively, using murine kidney and brain homogenates.
-
C174237-5mgBiochemical mechanism:Cell permeable: yesPrimary TargetGLS1Reversible: yesTarget IC50: 23 nM &: 28 nM, respectively, using murine kidney and brain homogenates.
-
C288513-100mgSelective TRPM4 blocker.
-
-
-
-